

Original Research Article

<https://doi.org/10.20546/ijcmas.2024.1309.016>

Modulation of $\gamma\delta$ T Cell Activity by Bisphosphonates in Neoplasms Resistant to Conventional Immunotherapy: An Update

Amália Cinthia Meneses do Rêgo¹ and Irami Araújo-Filho^{2*}

¹Institute of Teaching, Research, and Innovation, Liga Contra o Câncer – Natal – Brazil; Full Professor of the Postgraduate Program in Biotechnology at Potiguar University, Potiguar University (UnP) – Natal/RN - Brazil

²Institute of Teaching, Research, and Innovation, Liga Contra o Câncer – Natal – Brazil; Full Professor of the Postgraduate Program in Biotechnology at Potiguar University (UnP) – Natal/RN - Brazil. Full Professor, Department of Surgery, Potiguar University. Ph.D. in Health Science/ Natal-RN - Brazil

*Corresponding author

ABSTRACT

Keywords

Diphosphonates,
Immunomodulation,
Immunotherapy,
Tumor
Microenvironment

Article Info

Received:
20 July 2024
Accepted:
31 August 2024
Available Online:
10 September 2024

Bisphosphonates (BPs) are traditionally used to manage bone diseases, but recent evidence suggests they may play a significant role in cancer immunotherapy by modulating $\gamma\delta$ T cell activity. These agents, particularly nitrogen-containing bisphosphonates, activate V γ 9V δ 2 T cells, enhancing their cytotoxicity against tumor cells. However, gaps remain in understanding the differential effects of bisphosphonates on various $\gamma\delta$ T cell subsets, optimal dosing regimens, and their impact on the broader tumor microenvironment. This review synthesizes knowledge on bisphosphonate-induced $\gamma\delta$ T cell modulation, explores potential resistance mechanisms, and evaluates clinical applicability across different tumor types. It identifies biomarkers for patient stratification, considers synergistic effects with other therapies, and discusses the economic and practical implications of integrating bisphosphonates into standard oncology practice. Addressing these gaps is essential for optimizing bisphosphonates as immunomodulatory agents, advancing cancer immunotherapy strategies, and improving patient outcomes.

Introduction

Bisphosphonates (BPs) are widely recognized for their critical role in managing bone diseases such as osteoporosis, Paget's disease, and bone metastases. These agents, particularly nitrogen-containing bisphosphonates like zoledronic acid, primarily function by inhibiting the farnesyl pyrophosphate synthase in the mevalonate pathway, which reduces osteoclast-mediated bone

resorption (Wang *et al.*, 2023; Nie *et al.*, 2024; Zhang *et al.*, 2024).

However, recent studies have uncovered a potential immunomodulatory role for bisphosphonates, specifically their ability to modulate $\gamma\delta$ T cell activity, presenting new opportunities in cancer immunotherapy. The $\gamma\delta$ T cells, particularly the V γ 9V δ 2 subtype, are a unique subset of T lymphocytes that bridge innate and

adaptive immunity (Patra *et al.*, 2023; Liu *et al.*, 2023; Zheng *et al.*, 2022).

Unlike $\alpha\beta$ T cells, they do not require antigen presentation through major histocompatibility complex (MHC) molecules, allowing them to recognize and eliminate tumor cells directly. This property makes $\gamma\delta$ T cells promising candidates for immunotherapy, especially against tumors that evade conventional immune recognition (Hu *et al.*, 2017). Evidence suggests that nitrogen-containing bisphosphonates can act as potent activators of V γ 9V δ 2 T cells, enhancing their proliferation, activation, and cytotoxic functions against various malignancies (Bulut *et al.*, 2024).

The primary mechanism by which bisphosphonates activate $\gamma\delta$ T cells involves the inhibition of farnesyl pyrophosphate synthase in the mevalonate pathway. This leads to the accumulation of isopentenyl pyrophosphate (IPP), a phosphoantigen recognized by the T cell receptor (TCR) on V γ 9V δ 2 T cells (Hodgins *et al.*, 2017).

This interaction triggers the activation and expansion of these cells, suggesting that bisphosphonates might bridge innate and adaptive immune responses and provide dual benefits: reducing bone resorption and enhancing antitumor immunity (Cao *et al.*, 2023).

Despite promising results, several knowledge gaps remain. Firstly, the differential effects of various bisphosphonates on $\gamma\delta$ T cell subsets, such as naïve, memory, and effector populations, are not fully elucidated (Mizuta *et al.*, 2019).

While some studies suggest robust activation of $\gamma\delta$ T cells by bisphosphonates *in vitro*, little is known about how these effects translate *in vivo*, particularly in the complex, often immunosuppressive tumor microenvironment. Understanding how bisphosphonates differentially affect these subsets could lead to more precise and effective therapeutic strategies (Kim *et al.*, 2021; Tanaka *et al.*, 2017).

There is a lack of consensus regarding the optimal dosing and administration schedules for bisphosphonates to maximize their immunomodulatory effects while minimizing toxicity (Cho *et al.*, 2023). Some studies have explored low-dose regimens of zoledronic acid in combination with interleukin-2 (IL-2) to promote $\gamma\delta$ T cell expansion. Still, no standardized protocol considers the variability in cancer types or stages. This gap in

standardization presents a significant challenge for incorporating bisphosphonates into broader immunotherapy regimens (Sun *et al.*, 2021; Duault *et al.*, 2016; Merli *et al.*, 2020).

Another critical area of uncertainty is the impact of bisphosphonates on the broader immune landscape within the tumor microenvironment. While bisphosphonates are known to activate $\gamma\delta$ T cells, their effects on other immune cells, such as dendritic cells, macrophages, and regulatory T cells, remain poorly understood (Osada *et al.*, 2015; Yamaguchi *et al.*, 2022; Lee *et al.*, 2015).

Given that the efficacy of immunotherapy often depends on coordinated responses from multiple immune cell types, understanding how bisphosphonates interact with these cells is crucial (Tanaka *et al.*, 2018). Emerging evidence suggests that bisphosphonates may enhance tumor antigen presentation by dendritic cells, amplifying the overall antitumor response, but this requires further investigation (Hodgins *et al.*, 2017).

The long-term safety profile of bisphosphonates as immunomodulatory agents in cancer therapy is another area requiring exploration (Koh *et al.*, 2019). While these agents are generally well-tolerated in short-term use, prolonged administration has been associated with severe adverse effects, such as osteonecrosis of the jaw and atypical femoral fractures. Through well-designed clinical trials, comprehensive studies are needed to evaluate the risk-benefit ratio of bisphosphonates in this new therapeutic context (Man *et al.*, 2019; Parente-Pereira *et al.*, 2014; Nieda *et al.*, 2015).

Moreover, there is a lack of comprehensive studies examining the effects of bisphosphonates on $\gamma\delta$ T cells across different tumor types, particularly those resistant to conventional immunotherapies (Zang *et al.*, 2019). For instance, while some cancers, such as multiple myeloma and breast cancer, have shown responsiveness to $\gamma\delta$ T cell activation by bisphosphonates, other malignancies remain underexplored. Identifying which tumors most likely benefit from this approach is essential for developing tailored treatment strategies (Hodgins *et al.*, 2016; Wang *et al.*, 2018; Zhang *et al.*, 2024).

A significant gap in the literature pertains to the potential synergistic effects of bisphosphonates when combined with other immunotherapies, such as immune checkpoint inhibitors or chimeric antigen receptor (CAR) T-cell

therapy (Wang *et al.*, 2016). Preliminary studies indicate that bisphosphonates may enhance the efficacy of these treatments by modifying the immune microenvironment to be more conducive to antitumor activity. Still, this hypothesis remains to be rigorously tested in both preclinical and clinical settings (Bulut *et al.*, 2024).

The current literature lacks detailed insights into the specific clinical applications of bisphosphonates in modulating $\gamma\delta$ T cell activity for cancer treatment. While evidence suggests a beneficial role, the contexts in which they are most effective, such as specific cancer types, stages, or patient populations, are not well-defined. This represents a significant barrier to the broader adoption of bisphosphonates as a standard adjunctive therapy in oncology (Figure 1) (Man *et al.*, 2019; Nguyen *et al.*, 2024; Murday *et al.*, 2017).

This review aims to provide a comprehensive overview of the existing evidence regarding the modulation of $\gamma\delta$ T cell activity by bisphosphonates in cancer immunotherapy. By synthesizing findings from recent studies, we seek to identify areas of consensus and controversy, highlight existing gaps in understanding, and propose directions for future research to optimize the use of bisphosphonates as immunomodulatory agents in oncology.

Materials and Methods

This review was meticulously designed to evaluate the modulation of $\gamma\delta$ T cell activity by bisphosphonates in cancer immunotherapy. It employed a comprehensive search strategy across multiple high-impact databases. The selected databases included PubMed, Scopus, Embase, Web of Science, and SciELO, which were chosen for their extensive collections of peer-reviewed studies. Google Scholar was also utilized to access gray literature, ensuring the inclusion of significant studies unavailable in conventional academic databases. This broad approach aimed to capture a wide range of evidence pertinent to the research objectives. The search strategy employed a combination of Boolean operators and specific keywords such as "diphosphonates," "immunomodulation," "immunotherapy," "tumor microenvironment," "neoplasms," and "immunologic factors." boolean operators (AND, OR) were applied to refine the search parameters and optimize the retrieval of relevant studies. Inclusion criteria encompass various study designs, including randomized controlled trials, cohort studies, case-control studies, cross-sectional

analyses, case series, and systematic reviews. Eligible studies required a minimum sample size of 10 participants to investigate the immunomodulatory effects of bisphosphonates on $\gamma\delta$ T cells or their potential synergistic effects with other immunotherapies. Only studies with sufficient methodological detail for qualitative synthesis were included. Two independent reviewers blindly performed the study selection process, screening titles and abstracts to ensure relevance to the study's aims. Subsequently, full-text articles were reviewed in detail, with any discrepancies resolved by a third independent reviewer, maintaining a robust and unbiased selection process. This blinding ensured that the reviewers' assessments were not influenced by study details, thus enhancing the objectivity of the selection. Data extraction was conducted using a standardized form to capture key study characteristics, including authorship, year of publication, study design, sample size, population details, interventions, and outcomes related to $\gamma\delta$ T cell activity and interactions with the tumor microenvironment. The primary focus was identifying bisphosphonates' differential effects on $\gamma\delta$ T cell subsets, optimal dosing regimens, and the impact on other immune cells within the tumor microenvironment. A qualitative synthesis was employed, given the heterogeneity in study designs, populations, and outcomes. Thematic analysis was used to categorize and integrate findings across different studies, providing a comprehensive overview of existing evidence. This synthesis aimed to identify key findings, gaps, and controversies surrounding the role of bisphosphonates in modulating $\gamma\delta$ T cell activity in cancer. The review explored economic and practical considerations, such as the cost-effectiveness and feasibility of incorporating bisphosphonates into routine clinical practice. The conclusions drawn from this review are grounded in a critically evaluated body of scientific evidence, offering meaningful insights into the potential of bisphosphonates as immunomodulatory agents in oncology. By incorporating these detailed methodological elements, this review ensures a transparent, rigorous, and systematic approach to understanding the complex interactions between bisphosphonates, $\gamma\delta$ T cell activity, and the tumor microenvironment in cancer immunotherapy.

Results and Discussion

The specific impacts of bisphosphonates on different $\gamma\delta$ T cell subsets, including naïve, memory, and effector populations, are not fully understood. While

bisphosphonates, particularly nitrogen-containing types, activate $\gamma\delta$ T cells by increasing isopentenyl pyrophosphate (IPP) accumulation, the effects may differ among these subsets (Yamaguchi *et al.*, 2016).

The role of bisphosphonates (BPs) in modulating $\gamma\delta$ T cell activity within the context of cancer immunotherapy presents several complexities and areas requiring further exploration (Cho *et al.*, 2023; Zang *et al.*, 2019). A comprehensive understanding of these aspects is vital to enhance the effectiveness of bisphosphonate-based therapies and identify opportunities for improved patient outcomes (Zheng *et al.*, 2022; Merli *et al.*, 2020).

Naïve cells may have higher activation thresholds than memory or effector $\gamma\delta$ T cells, which could impact their expansion and function. The effector cells may show enhanced cytotoxic responses in a tumor context, which is highly influenced by the tumor microenvironment. Further studies should aim to elucidate these differential effects in vivo (Hodgins *et al.*, 2017; Okuno *et al.*, 2020).

The translation of in vitro findings on bisphosphonate-induced $\gamma\delta$ T cell activation to in vivo settings remains unclear. Despite in vitro studies demonstrating the potential of bisphosphonates to activate V γ 9V δ 2 T cells, the complex and often immunosuppressive nature of the tumor microenvironment, characterized by factors like hypoxia and regulatory cells, could mitigate these effects (Hodgins *et al.*, 2016; Parente-Pereira *et al.*, 2014). However, future research must focus on comprehensive in vivo models and clinical trials to clarify how bisphosphonate-induced $\gamma\delta$ T cell activation influences outcomes in real-world conditions (Figure 2) (Girard *et al.*, 2020).

The broader impact of bisphosphonates on the tumor microenvironment is crucial for maximizing their therapeutic potential. While much attention has focused on their effects on $\gamma\delta$ T cells, bisphosphonates also influence other immune cells, such as dendritic cells, macrophages, and regulatory T cells (Man *et al.*, 2019; Osada *et al.*, 2015). Studies suggest that bisphosphonates may enhance the antigen-presenting capacity of dendritic cells or polarize macrophages toward a pro-inflammatory phenotype, potentially amplifying the overall antitumor response (Parente-Pereira *et al.*, 2014).

There is no consensus on the optimal dosing and administration schedules for bisphosphonates to maximize their immunomodulatory effects while

minimizing toxicity (Murday *et al.*, 2017). Existing studies have investigated low-dose regimens in conjunction with agents like interleukin-2 (IL-2), but variable responses across different cancer types and stages make standardizing protocols challenging (Poonia *et al.*, 2016).

The broader effects of bisphosphonates on the immune landscape within the tumor microenvironment are not well-characterized. While $\gamma\delta$ T cell activation is established, the impact on other immune cells, such as dendritic cells, macrophages, and regulatory T cells, needs further exploration (Hodgins *et al.*, 2016). These interactions is vital for predicting therapeutic efficacy, as effective immunotherapy often relies on coordinated responses from multiple immune cells (Okuno *et al.*, 2020).

One critical gap in current research pertains to the mechanisms by which certain tumors exhibit resistance to the immunomodulatory effects of bisphosphonates. Tumors may develop resistance through several pathways, such as altering the expression of phosphoantigens, which are crucial for $\gamma\delta$ T cell activation (Merli *et al.*, 2020; Kar *et al.*, 2016).

This alteration can occur due to changes in the tumor microenvironment that affect the mevalonate pathway, reducing the accumulation of intermediates like isopentenyl pyrophosphate (IPP) necessary for $\gamma\delta$ T cell stimulation (Mizuta *et al.*, 2019). Tumors may increase the expression of immune checkpoint molecules, such as PD-L1, which inhibit the immune response by $\gamma\delta$ T cells (Tanaka *et al.*, 2018). These resistance mechanisms could inform new combination therapies, such as using bisphosphonates alongside immune checkpoint inhibitors, to overcome the tumor's evasion strategies and potentiate the immune response (Acosta-Ramirez *et al.*, 2016).

The long-term safety profile of bisphosphonates in cancer therapy is a critical concern. Prolonged use is associated with adverse effects like osteonecrosis of the jaw and atypical femoral fractures, which can limit their application in oncology (Lee *et al.*, 2015). These risks, particularly in long-term immunomodulatory use, requires extensive safety monitoring, risk stratification, and mitigation strategies (Girard *et al.*, 2020).

Long-term safety and tolerability remain significant concerns, particularly given the potential adverse effects

associated with bisphosphonates, such as osteonecrosis of the jaw and atypical femoral fractures (Poonia *et al.*, 2016; Parente-Pereira *et al.*, 2014).

A deeper exploration of strategies to mitigate these risks, such as adjusting dosing schedules, combining with other therapeutic agents, or developing new bisphosphonate formulations, is essential. Ongoing surveillance and post-marketing studies should assess long-term outcomes and adverse events to refine treatment protocols and ensure patient safety (Kar *et al.*, 2016).

The potential synergy between bisphosphonates and other immunotherapies, such as checkpoint inhibitors or CAR T cells, remains an exciting yet underexplored area (Duault *et al.*, 2016). Preliminary evidence suggests that bisphosphonates modify the tumor microenvironment to enhance the efficacy of these treatments, but the mechanisms remain unclear. Further research is required to understand the effects of bisphosphonates across a broader range of tumor types, particularly those resistant to conventional immunotherapies (Nguyen *et al.*, 2024; Acosta-Ramirez *et al.*, 2016).

The response to $\gamma\delta$ T cell activation by bisphosphonates may vary significantly depending on the tumor's genetic and molecular characteristics, the presence of specific antigens, or the overall immune landscape (Zheng *et al.*, 2022; Hu *et al.*, 2017; Bulut *et al.*, 2024). Identifying which tumors are most likely to respond to bisphosphonate-based therapies will help refine their use and guide future clinical trials (Parente-Pereira *et al.*, 2014).

The potential for bisphosphonates to synergize with other immunotherapies, such as checkpoint inhibitors or CAR-T cell therapies, represents a promising avenue for future research (Bulut *et al.*, 2024). Preliminary evidence suggests that bisphosphonates may enhance the efficacy of these therapies by modulating the tumor microenvironment to be more conducive to immune activity (Merli *et al.*, 2020). However, more detailed investigations are needed to define the optimal combinations, dosing regimens, and sequencing of these therapies to maximize patient outcomes (Yamaguchi *et al.*, 2016).

The clinical applicability of bisphosphonates for modulating $\gamma\delta$ T cell activity across different tumor types is still largely undefined. While there is evidence supporting their use in cancers like multiple myeloma

and breast cancer, their efficacy in other malignancies has not been thoroughly explored (Cao *et al.*, 2023; Mizuta *et al.*, 2019).

Research should aim to identify which tumor types are most likely to benefit from bisphosphonate-induced $\gamma\delta$ T cell activation, considering factors such as tumor microenvironment, immune evasion mechanisms, and genetic profiles (Nguyen *et al.*, 2024; Kopecka *et al.*, 2016).

A thorough comparison of different bisphosphonates—such as zoledronic acid, alendronate, and risedronate—is essential to understand their differential effects on $\gamma\delta$ T cell activation and interaction with the tumor microenvironment (Girard *et al.*, 2020). Current literature suggests that while all these agents can enhance $\gamma\delta$ T cell activity, they differ in their potency, duration of action, and safety profiles (Le Burel *et al.*, 2017).


For instance, zoledronic acid is known for its potent and sustained activation of $\gamma\delta$ T cells, but its use is associated with more frequent adverse effects. In contrast, other bisphosphonates may offer a more favorable safety profile but less robust immunomodulatory activity (Hodgins *et al.*, 2016; Wang *et al.*, 2018; Zhang *et al.*, 2024). Comparative studies should investigate these differences, focusing on optimizing dosing regimens and administration routes to balance efficacy and safety across various cancer types and stages (Eiraku *et al.*, 2018).

The current literature lacks standardization in study designs, which complicates comparisons and limits the generalizability of findings. Variability in patient populations, dosing regimens, outcome measures, and follow-up periods makes it challenging to draw definitive conclusions (Fowler *et al.*, 2014).

The trials should adhere to standardized protocols with well-defined inclusion criteria, consistent dosing schedules, and validated endpoints to allow for more robust meta-analyses and systematic reviews (Zang *et al.*, 2019).


An area not fully explored is the potential mechanisms of resistance by which certain tumors may evade the immunomodulatory effects of bisphosphonates. Tumor cells may alter the expression of phosphoantigens or upregulate immune checkpoint molecules that inhibit $\gamma\delta$ T cell activity (Hu *et al.*, 2017; Duault *et al.*, 2016).

Figure.1 $\gamma\delta$ T cells directly kill tumor cells and indirectly enhance antitumor immunity by activating other immune cells.



Source: <https://www.nature.com/articles/s41568-019-0153-5>

Figure.2 Overview of $\gamma\delta$ T Cell Interactions in Cancer Immunity.



Source: <https://doi.org/10.3389/fimmu.2022.894315>

For example, tumors could modify the presentation or recognition of IPP, limiting the activation of V γ 9V δ 2 T cells. Understanding these resistance mechanisms is crucial to developing strategies, such as combining bisphosphonates with agents that block these escape pathways (Acosta-Ramirez *et al.*, 2016).

Identifying biomarkers or genetic profiles that could help stratify patients who are most likely to benefit from bisphosphonate-based immunotherapy is necessary (Girard *et al.*, 2020). The expression levels of enzymes in the mevalonate pathway, specific $\gamma\delta$ T cell receptors, or the presence of tumor antigens may predict responsiveness to bisphosphonates. Developing reliable biomarkers could guide patient selection and improve clinical outcomes by tailoring treatments to those most likely to benefit (Parente-Pereira *et al.*, 2014; Yamaguchi *et al.*, 2016).

The stratification of patients based on biomarkers or genetic profiles represents another area of interest. Identifying which patients are most likely to benefit from bisphosphonate-based immunotherapy could lead to more personalized treatment approaches (Osada *et al.*, 2015; Man *et al.*, 2019).

Potential biomarkers include the expression levels of specific $\gamma\delta$ T cell subtypes, such as V γ 9V δ 2, or tumor-specific characteristics like antigen profiles or metabolic signatures linked to the mevalonate pathway (Patra *et al.*, 2023; Zheng *et al.*, 2022; Merli *et al.*, 2020). A detailed discussion is warranted on integrating these biomarkers into clinical practice, optimizing patient selection, and improving therapeutic outcomes. Studies should focus on validating these biomarkers in diverse populations and across various cancer types to establish their predictive value in clinical settings (Murday *et al.*, 2017; Yamaguchi *et al.*, 2016; Zang *et al.*, 2019; Poonia *et al.*, 2016).

Comparative studies are necessary to evaluate the efficacy of different bisphosphonates and their combinations with other therapies across various cancer types and stages. Such studies could provide insights into which bisphosphonates are most effective in specific contexts and help refine treatment protocols (Cho *et al.*, 2023; Acosta-Ramirez *et al.*, 2016). They could explore the differential effects of bisphosphonates in combination with existing immunotherapies, like immune checkpoint inhibitors or adoptive cell therapies (Koh *et al.*, 2019).

Finally, economic and practical considerations are vital for successfully integrating bisphosphonates into routine clinical practice. Evaluating the cost-effectiveness of bisphosphonates as immunomodulatory agents, their accessibility, and logistical challenges, such as administration routes and monitoring requirements, is crucial for broad adoption (Yamaguchi *et al.*, 2016; Girard *et al.*, 2020).

These factors should be studied in parallel with clinical trials to ensure that bisphosphonates can be feasibly implemented in diverse healthcare settings. Incorporating bisphosphonates into routine clinical practice also raises several economic and practical considerations (Zhang *et al.*, 2024; Patra *et al.*, 2023; Liu *et al.*, 2023). Cost-effectiveness analysis is needed to determine whether the benefits of bisphosphonate-based immunotherapy outweigh the costs, particularly in resource-limited settings (Patra *et al.*, 2023; Sun *et al.*, 2021).

Practical issues such as drug accessibility, administration routes, and the need for regular monitoring must be addressed. These factors will influence the feasibility of integrating bisphosphonates into standard care protocols and may require tailored approaches depending on the healthcare setting (Yamaguchi *et al.*, 2016; Fowler *et al.*, 2014).

In conclusion, these gaps are essential for optimizing bisphosphonates as immunomodulatory agents in cancer therapy. Research should focus on elucidating resistance mechanisms, refining patient stratification methods, conducting comparative studies, and considering economic and practical factors to enhance the clinical utility of bisphosphonates in oncology. We can better understand how to leverage bisphosphonates to improve cancer immunotherapy outcomes by exploring these areas in depth.

Acknowledgements

The authors thank the Federal University of Rio Grande do Norte, Potiguar University, and Liga Contra o Cancer for supporting this study.

Author Contributions

Amália Cinthia Meneses do Rêgo: Investigation, formal analysis, writing—original draft. Irami Araújo-Filho: Validation, methodology, writing—reviewing.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethical Approval Not applicable.

Consent to Participate Not applicable.

Consent to Publish Not applicable.

Conflict of Interest The authors declare no competing interests.

References

- Acosta-Ramirez E, Tram C, Kampen R M, Tillman M R, Schwendener R A, Xing Z, *et al.*, Respiratory macrophages regulate CD4 T memory responses to mucosal immunization with recombinant adenovirus-based vaccines. *Cell Immunol.* 2016 Dec;310:53-62. <https://doi.org/10.1016/j.cellimm.2016.07.006>.
- Bulut O, Kilic G, Debisarun PA, Röring RJ, Sun S, Kolkman M, *et al.*, Alendronate modulates cytokine responses in healthy young individuals after BCG vaccination. *ImmunolLett.* 2024 Jun;267:106851. <https://doi.org/10.1016/j.imlet.2024.106851>.
- Cao Y, Qiao B, Chen Q, Xie Z, Dou X, Xu L, *et al.*, Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy. *Acta Biomater.* 2023 Apr 1;160:239-251. <https://doi.org/10.1016/j.actbio.2023.02.006>.
- Cho S Y, Jeong S M, Jeon Y J, Yang S J, Hwang J E, Yoo BM, *et al.*, WT1 pulsed human CD141+ dendritic cell vaccine has high potential in solid tumor-targeted immunotherapy. *Int J Mol Sci.* 2023 Jan 12;24(2):1501. <https://doi.org/10.3390/ijms24021501>.
- Duault C, Franchini D M, Familiades J, Cayrol C, Roga S, Girard J P, *et al.*, TCRV γ 9 $\gamma\delta$ T cell response to IL-33: a CD4 T cell-dependent mechanism. *J Immunol.* 2016 Jan 1;196(1):493-502. <https://doi.org/10.4049/jimmunol.1500260>.
- Eiraku Y, Terunuma H, Yagi M, Deng X, Nicol A J, Nieda M. Dendritic cells cross-talk with tumour antigen-specific CD8+ T cells, V γ 9 $\gamma\delta$ T cells and V α 24NKT cells in patients with glioblastoma multiforme and in healthy donors. *Clin Exp Immunol.* 2018 Oct;194(1):54-66. <https://doi.org/10.1111/cei.13185>.
- Fowler D W, Copier J, Dalgleish A G, Bodman-Smith M D. Zoledronic acid causes $\gamma\delta$ T cells to target monocytes and down-modulate inflammatory homing. *Immunology.* 2014 Dec;143(4):539-49. <https://doi.org/10.1111/imm.12331>.
- Girard P, Ponsard B, Charles J, Chaperot L, Aspod C. Potent bidirectional cross-talk between plasmacytoid dendritic cells and $\gamma\delta$ T cells through BTN3A, type I/II IFNs and immune checkpoints. *Front Immunol.* 2020 May 6;11:861. <https://doi.org/10.3389/fimmu.2020.00861>.
- Hodgins N O, Al-Jamal W T, Wang J T, Klippstein R, Costa P M, Sosabowski J K, *et al.*, Investigating in vitro and in vivo $\alpha\beta$ 6 integrin receptor-targeting liposomal alendronate for combinatory $\gamma\delta$ T cell immunotherapy. *J Control Release.* 2017 Jun 28;256:141-152. <https://doi.org/10.1016/j.jconrel.2017.04.025>.
- Hodgins N O, Al-Jamal W T, Wang J T, Parente-Pereira A C, Liu M, Maher J, *et al.*, In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with $\gamma\delta$ T cell immunotherapy in mice. *J Control Release.* 2016 Nov 10;241:229-241. <https://doi.org/10.1016/j.jconrel.2016.09.023>.
- Hodgins N O, Wang J T, Al-Jamal K T. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitizers of $\gamma\delta$ T cells for anticancer immunotherapy. *Adv Drug Deliv Rev.* 2017 May 15;114:143-160. <https://doi.org/10.1016/j.addr.2017.07.003>.
- Hu L, Wen Y, Xu J, Wu T, Zhang C, Wang J, *et al.*, Pretreatment with bisphosphonate enhances osteogenesis of bone marrow mesenchymal stem cells. *StemCells Dev.* 2017 Jan 15;26(2):123-132. <https://doi.org/10.1089/scd.2016.0173>.
- Kar S, Colino J, Snapper C M. Distinct cellular pathways for induction of CD4+ T cell-dependent antibody responses to antigen expressed by intact bacteria versus isolated soluble antigen. *J Immunol.* 2016 May 15;196(10): 4204-13. <https://doi.org/10.4049/jimmunol.1502550>.
- Kim M, Kim H, Han M, Hwang H J, Kim H, Im H J, *et al.*, Characteristics of human peripheral blood $\gamma\delta$

- T cells expanded with zoledronate. *Anticancer Res.* 2021 Dec;41(12):6031-6038. <https://doi.org/10.21873/anticancer.15422>.
- Koh KN, Im HJ, Kim H, Kim N, Choi ES, Park CJ, *et al.*, $\alpha\beta$ T-cell-depleted haploidentical hematopoietic cell transplantation and zoledronate/interleukin-2 therapy in children with relapsed, high-risk neuroblastoma. *Bone Marrow Transplant.* 2019 Feb;54(2):348-352. <https://doi.org/10.1038/s41409-018-0305-3>.
- Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Pinzòn-Daza ML, *et al.*, Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. *Oncotarget.* 2016 Apr 12;7(15):20753-72. <https://doi.org/10.18632/oncotarget.8012>.
- Le Burel S, Thepenier C, Boutin L, Lataillade JJ, Peltzer J. Effect of mesenchymal stromal cells on T cells in a septic context: immunosuppression or immunostimulation? *StemCells Dev.* 2017 Oct 15;26(20):1477-1489. <https://doi.org/10.1089/scd.2016.0184>.
- Lee YT, Kim KH, Hwang HS, Lee Y, Kwon YM, Ko EJ, *et al.*, Innate and adaptive cellular phenotypes contributing to pulmonary disease in mice after respiratory syncytial virus immunization and infection. *Virology.* 2015 Nov;485:36-46. <https://doi.org/10.1016/j.virol.2015.07.001>.
- Liu B, Yang Q, Cheng Y, Liu M, Ji Q, Zhang B, *et al.*, Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression. *Acta Biomater.* 2023 Aug;166:640-654. <https://doi.org/10.1016/j.actbio.2023.05.038>.
- Man F, Lim L, Volpe A, Gabizon A, Shmeeda H, Draper B, *et al.*, In vivo PET tracking of ^{89}Zr -labeled $\text{V}\gamma 9\text{V}\delta 2$ T cells to mouse xenograft breast tumors activated with liposomal alendronate. *Mol Ther.* 2019 Jan 2;27(1):219-229. <https://doi.org/10.1016/j.ymthe.2018.10.006>.
- Merli P, Algeri M, Galaverna F, Milano GM, Bertaina V, Biagini S, *et al.*, Immune modulation properties of zoledronic acid on $\text{TcR}\gamma\delta$ T-lymphocytes after $\text{TcR}\alpha\beta/\text{CD}19$ -depleted haploidentical stem cell transplantation: an analysis on 46 pediatric patients affected by acute leukemia. *Front Immunol.* 2020 May 12;11:699. <https://doi.org/10.3389/fimmu.2020.00699>.
- Mizuta S, Tagod MSO, Iwasaki M, Nakamura Y, Senju H, Mukae H, *et al.*, Synthesis and immunomodulatory activity of fluorine-containing bisphosphonates. *ChemMedChem.* 2019 Feb 19;14(4):462-468. <https://doi.org/10.1002/cmdc.201800764>.
- Murday AS, Chaudhry S, Pauza CD. Interleukin-18 activates $\text{V}\gamma 9\text{V}\delta 2^+$ T cells from HIV-positive individuals: recovering the response to phosphoantigen. *Immunology.* 2017 Aug;151(4):385-394. <https://doi.org/10.1111/imm.12735>.
- Nguyen TT, Nguyen BT, Tran KV, Tran CK, Trinh HL, Hoang HH, *et al.*, Experience of autologous immunotherapy for non-small cell lung cancer using zoledronate-activated gammadelta T cells. *Clin Lab.* 2024 Jan 1;70(1). <https://doi.org/10.7754/Clin.Lab.2023.230663>.
- Nie M, Wu S, Chen Y, Wu Y, Chen R, Liu Y, *et al.*, Micronanoparticled risedronate exhibits potent vaccine adjuvant effects. *J Control Release.* 2024 Jan;365:369-383. <https://doi.org/10.1016/j.jconrel.2023.11.025>.
- Nieda M, Terunuma H, Eiraku Y, Deng X, Nicol AJ. Effective induction of melanoma-antigen-specific $\text{CD}8^+$ T cells via $\text{V}\gamma 9\gamma\delta$ T cell expansion by $\text{CD}56(\text{high}^+)$ interferon- α -induced dendritic cells. *Exp Dermatol.* 2015 Jan;24(1):35-41. <https://doi.org/10.1111/exd.12581>.
- Okuno D, Sugiura Y, Sakamoto N, Tagod MSO, Iwasaki M, Noda S, *et al.*, Comparison of a novel bisphosphonate prodrug and zoledronic acid in the induction of cytotoxicity in human $\text{V}\gamma 2\text{V}\delta 2$ T cells. *Front Immunol.* 2020 Jul 21;11:1405. <https://doi.org/10.3389/fimmu.2020.01405>.
- Osada T, Nagaoka K, Takahara M, Yang XY, Liu CX, Guo H, *et al.*, Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors. *J Immunother.* 2015 May;38(4):155-64. <https://doi.org/10.1097/CJI.0000000000000075>.
- Parente-Pereira AC, Shmeeda H, Whilding LM, Zambirinis CP, Foster J, van der Stegen SJ, *et al.*, Adoptive immunotherapy of epithelial ovarian cancer with $\text{V}\gamma 9\text{V}\delta 2$ T cells, potentiated by liposomal alendronic acid. *J Immunol.* 2014 Dec 1;193(11):5557-66. <https://doi.org/10.4049/jimmunol.1402200>.
- Patra S, Ghosal S, Shand H, Mondal R, Rath A, Kumar

- Jana S, *et al.*, Function of gamma delta ($\gamma\delta$) T cell in cancer with special emphasis on cervical cancer. *Hum Immunol.* 2023 Dec;84(12):110724. <https://doi.org/10.1016/j.humimm.2023.110724>.
- Poonia B. Adoptive transfer of aminobisphosphate-expanded V γ 9V δ 2+ T cells does not control HIV replication in a humanized mouse model. *Immunotherapy.* 2016 May;8(5):521-6. <https://doi.org/10.2217/imt-2015-0003>.
- Sun B, Zhao X, Wu Y, Cao P, Movahedi F, Liu J, *et al.*, Mannose-functionalized biodegradable nanoparticles efficiently deliver DNA vaccine and promote anti-tumor immunity. *ACS Appl Mater Interfaces.* 2021 Mar 31;13(12):14015-14027. <https://doi.org/10.1021/acsami.1c01401>.
- Tanaka Y, Iwasaki M, Murata-Hirai K, Matsumoto K, Hayashi K, Okamura H, *et al.*, Anti-tumor activity and immunotherapeutic potential of a bisphosphonate prodrug. *Sci Rep.* 2017 Jul 20;7(1):5987. <https://doi.org/10.1038/s41598-017-05553-0>.
- Tanaka Y, Murata-Hirai K, Iwasaki M, Matsumoto K, Hayashi K, Kumagai A, *et al.*, Expansion of human $\gamma\delta$ T cells for adoptive immunotherapy using a bisphosphonate prodrug. *Cancer Sci.* 2018 Mar;109(3):587-599. <https://doi.org/10.1111/cas.13491>.
- Wang L, Li Z, Ciric B, Safavi F, Zhang GX, Rostami A. Selective depletion of CD11c+ CD11b+ dendritic cells partially abrogates tolerogenic effects of intravenous MOG in murine EAE. *Eur J Immunol.* 2016 Oct;46(10):2454-2466. <https://doi.org/10.1002/eji.201546274>.
- Wang S, Li H, Ye C, Lin P, Li B, Zhang W, *et al.*, Valproic acid combined with zoledronate enhance $\gamma\delta$ T cell-mediated cytotoxicity against osteosarcoma cells via the accumulation of mevalonate pathway intermediates. *Front Immunol.* 2018 Feb 27;9:377. <https://doi.org/10.3389/fimmu.2018.00377>.
- Wang Y, Wang L, Seo N, Okumura S, Hayashi T, Akahori Y, *et al.*, CAR-modified V γ 9V δ 2 T cells propagated using a novel bisphosphonate prodrug for allogeneic adoptive immunotherapy. *Int J Mol Sci.* 2023 Jun 29;24(13):10873. <https://doi.org/10.3390/ijms241310873>.
- Yamaguchi Y, Katata Y, Okawaki M, Sawaki A, Yamamura M. A prospective observational study of adoptive immunotherapy for cancer using zoledronate-activated killer (ZAK) cells - an analysis for patients with incurable pancreatic cancer. *Anticancer Res.* 2022 Feb;42(2):1181-1187. <https://doi.org/10.21873/anticancerres.15584>.
- Yamaguchi Y, Katata Y, Okawaki M, Sawaki A, Yamamura M. A prospective observational study of adoptive immunotherapy for cancer using zoledronate-activated killer (ZAK) cells - an analysis for patients with incurable pancreatic cancer. *Anticancer Res.* 2016 May;36(5):2307-13. Retraction in: *Anticancer Res.* 2021 Aug;41(8):4181. <https://doi.org/10.21873/anticancerres.41.8.4181>.
- Zang X, Zhang X, Hu H, Qiao M, Zhao X, Deng Y, *et al.*, Targeted delivery of zoledronate to tumor-associated macrophages for cancer immunotherapy. *Mol Pharm.* 2019 May 6;16(5):2249-2258. <https://doi.org/10.1021/acs.molpharmaceut.9b00261>.
- Zhang X, Wei M, Zhang Z, Zeng Y, Zou F, Zhang S, *et al.*, Zoledronate-functionalized manganese-hydroxyapatite amorphous particles: a potent adjuvant for subunit vaccines and cancer immunotherapy. *J Control Release.* 2024 Mar;367:13-26. <https://doi.org/10.1016/j.jconrel.2024.01.033>.
- Zheng Y, Wang PP, Fu Y, Chen YY, Ding ZY. Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer. *Int Immunopharmacol.* 2022 Sep;110:109030. <https://doi.org/10.1016/j.intimp.2022.109030>.

How to cite this article:

Amália Cinthia Meneses do Rêgo and Irami Araújo-Filho. 2024. Modulation of $\gamma\delta$ T Cell Activity by Bisphosphonates in Neoplasms Resistant to Conventional Immunotherapy: An Update. *Int.J.Curr.Microbiol.App.Sci.* 13(9): 149-158. doi: <https://doi.org/10.20546/ijcmas.2024.1309.016>